This funding opportunity supports research advancing prevention approaches to reduce prenatal alcohol exposure and interventions for fetal alcohol spectrum disorders (FASD) throughout the lifespan. It employs an Exploratory/Developmental Phased Award (R61/R33) mechanism, where the R61 phase funds pilot studies or secondary data analysis, and the R33 phase supports expanded hypothesis testing based on milestone achievement. Clinical trials are optional but given highest priority.
Eligible applicants include a wide range of U.S. entities such as state and local governments, nonprofits, for-profit organizations, small businesses, tribal governments, and institutions of higher education. Specific eligibility details are provided in the NOFO text.
